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A B S T R A C T
The research entails the development of two models that can be used to predict the tox-
icity of compounds suspected of having anti-leukemia activity, the two models, one for MOLT-4
and the other for P388 cell lines, were developed by carefully selecting 5 descriptors in each
case from a pool of 4900 molecular descriptors using GA-MLR method. The ability of the
models to predict chemicals that were not used in the preparation set was evaluated by
validating the models internally [Q2CV MOLT-4 = 0.644 and Q2CV (P388) = 0.641] and exter-
nally [R2pred (P388) = 0.662 and R2pred (MOLT-4) = 0.679], other criteria such as r2m, R2p, k and k′
were also determined and were found to support R2pred results of the models. The effects of
every descriptor in the model were dictated by calculating their individual mean effect to
(pLC50) the toxicities of the compounds. SpMax7_Bhm (1.697) and RDF145u (−4.300) influ-
enced the models the most, while in MOLT-4 the descriptors with the least effect was
n-isopropyl (0.0343) and for P388 is 1.162. The models were further validated by subjecting
them to y-randomization which finally confirmed the robustness of the models developed.
© 2016 Production and hosting by Elsevier B.V. on behalf of Beni-Suef University. This is









Cancer is a standout among the most far reaching and dreaded
sicknesses in the Western world today to a great extent in light
of the fact that it is considered difficult to cure, which is as a
result of the uncontrolled multiplication of slightly modified
normal human cells. The dominant part of medications uti-
lized for the treatment of cancer today is cytotoxic (cell-
killing) sedates that work by mutating the cell DNA and
influencing its function. Cytotoxic medications can possibly be
extremely unsafe to the body unless they are used specifi-
cally to target tumor cells. This could be attributed to non-
metastasis cancer hence excluding cancer types like leukemia.
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Cancer drugs are divided into two broad types i.e. cytotoxic (cell
executing) drugs and cytostatic (cell stabilizing medications).
Both classifications lead to a considerable decrease of the tumor
size in light of the fact that cancer cells (for different reasons)
have such a high death rate, to the point that it is basically
keeping them from separating and in time leading to a criti-
cal diminishment in the populace target cells (Adhikari et al.,
2015).
Quantitative structure–activity relationship (QSAR) and quan-
titative structure–toxicity relationship (QSTR) make it
conceivable to predict the activity/toxicity of a given com-
pound as a function of its molecular descriptors. In this study,
the genetic algorithm procedure was utilized as a determina-
tion device to choose the most significant descriptors (Ahmad
and Gromiha, 2003; Gomes et al., 2001; Waller and Bradley, 1999).
Genetic functional approximation system was initially created
by Leardi, Boggia and Terrile in 1992 (Leardi et al., 1992), and
the starting stride in performing genetic algorithm is the gen-
eration of vast number of haphazardly selected variables in
terms of activities (QSAR), where the variables incorporated into
every model are called molecular descriptor (Dimic´ et al., 2015).
These selected subsets of descriptors are further assessed by
their ability to anticipate inhibition activity. Here, the param-
eter used was cross-validation correlation coefficient of leave-
one-out (Q2LOO derived based on MLR) (Leardi et al., 1992). The
following step is to prohibit the less important subsets, and
after that breed the remaining subsets last, before the opti-
mization is completed. There are various points of interest to
the utilization of QSARs to predict toxicity of drugs. The key
points of interest are the actualities that prediction of drug tox-
icities can be elucidated by relaying the information gathered
from the structure of the compounds to their toxicity. QSTR
can be used to predict the toxicity of unknown chemicals in
many ways. In industries, these models can be applied to screen
new compounds and help with the procedure for designing less
toxic but potent drugs. Some QSAR models that are commer-
cially employed in the prediction of chemical toxicity (Thomas
et al., 2007) were reported by Supratik Kar (2010) and Tsakovska
et al. (2008). Other reviews of cytotoxic nature of drugs include
models for rat (rodent and mouse) toxicity assessment (Cronin
and Schultz, 2003; Devillers and Devillers, 2009; Tsakovska et al.,
2008). Programming tools equipped for predicting endpoints
such as toxicity, for example, ACD/Tox Suite that predicts tox-
icity in rodents irrespective of the mode of delivery and other
QSARs statistically-based programs TOPKAT and MCASE, were
reported by Silvia et al. in the JRC science and technical reports
(Silvia et al., 2010).
There are, be that as it may, various reasonable confine-
ments in modeling toxicity of chemicals, put essentially, we
do not have enough biological information with which to create
and accept prescient models. This is a crucial and common-
sense confinement that overrides all others. The biological
information has been accessed by theoretical scientists. This
issue is exacerbated by an absence of acknowledgment of the
uneven nature of the information, and the limitation that low-
quality data could bring by influencing the models to be
developed. A late examination of databases of information on
chemicals used in cancer study uncovered a stressing absence
of consistency within and between databases (Gottmann et al.,
2001; Helma et al., 2000). Obviously, with just a predeter-
mined number of enzyme/receptor frameworks known to
mediate adverse effects and even less available in a QSAR
setting (because of lacking fact-finding information), false-
negative results will dependably be available. It will specifically
perceive conceivably unsafe chemicals connected with sig-
nificant biochemical reaction and take into consideration
disposing of them at an opportune time. Secondly, a broadly
utilized database of this kind may lessen the quantity of gen-
erally doubly-piloted toxicity tests at research institutes or
centers concentrating on firmly related biomedical targets,
hence this paper aims at maximizing the chances of identi-
fying toxic anticancer drugs irrespective of their mode of action
in the mitigation of leukemia cells, since a metastatic disease
type like leukemia involves so many enzymatic reactions that
cannot be completely understood interacting with the drug
process this models will help by increasing the large net of ap-
plicability domain of quantitative structural toxicity relationship
models for effective screening of anticancer drugs in general.
2. Materials and methods
2.1. Experimental dataset
In the present study, we utilized a dataset of 112 compounds
whose anticancer toxicity against human acute lymphoblas-
tic leukemia (MOLT-4) and multidrug-resistant P388 leukemia
cell line has been beforehand described (Supplementary Table).
The dataset along with their structures, NSC and CAS numbers
were taken from the drug discovery and development arm of
the National Cancer Institute (NCI), the Developmental Thera-
peutics Program (DTP). Eligible compounds were determined
by reviewing and curating the raw data collected from the lit-
erature (NCI database). The data set include antimetabolites,
alkylating agents,DNA-binding agents,RNA-binding agents etc. which
encompass aminopterin and camptothecin derivatives, col-
chicine analogs. Other compounds such as dolastine, glycinate,
chlorozotocin as well as other heterocyclic compounds are
among the selected dataset. The empirical toxicity (-LogLC50)
values of the studied compounds collected were presented in
Table 1 and the scope of the action information differs from
1.3 to 8 (µM) for MOLT-4 and 1.1 to 5.6 (µM) for P388.
2.2. Geometry optimization and molecular descriptors
calculation
The 2D structures of the compounds in the Supplementary Table
were drawn using chemdraw programming (Li et al., 2004) and
these structures affirmed with the mol document recovered
(ChemicalBook) through their individual CAS number. The
spatial conformations of the compounds were resolved uti-
lizing the Spartan 14 V1.1.4 wavefunction programming package.
The chemical structures were initially minimized by Molecu-
lar Mechanics Force Field (MM+) count to uproot strain energy
before subjecting it to quantum chemical estimations. For this
computation DFT (density functional theory) method for com-
plete geometric optimization of the structures was employed.
These methods have turned out to be extremely well known
lately in light of the fact that they can attain comparable
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1 11-Formyl-20(RS)-camptothecin 606,172 4 4.259 – –
2 11-Hydroxymethyl-20(RS)-camptothecin 606,173 4 4.013 – –
3 14-Chloro-20(S)-camptothecin hydrate 643,833 4 4.216 – –
4 2′-Deoxy-5-fluorouridine 27,640 2.6 1.932 2.8 3.124
5 3-HP 95,678 3 2.821 3 2.932
6 5,6-Dihydro-5-azacytidine 264,880 2.6 2.930 2.6 3.039
7 5-Aza-2′-deoxycytidine 127,716 3.4 2.707a 3.5 2.931
8 5-Azacytidine 102,816 3.2 2.857 3.1 3.077
9 5-HP 107,392 2.8 2.844 2.8 2.868
10 7-Chlorocamptothecin 249,910 4 4.228 – –
11 9-Amino-20-(R,S)-camptothecin 629,971 1.3 2.805* – –
12 Acivicin 163,501 3 0.025*,a 3 2.943
13 Allocolchicine 406,042 4 3.793a – –
14 Alpha-TGDR 71,851 2.3 2.662 2.3 2.961
15 Aminopterin derivative1 132,483 4 3.756 4 4.618
16 Aminopterin derivative2 184,692 4 4.018 5.5 5.101
17 Aminopterin derivative3 134,033 4 3.968a 4 3.991
18 Amonafide 308,847 3.7 3.893 3.8 3.915
19 AN antifol 623,017 4 3.742 4 4.285
20 Anthrapyrazole derivative 355,644 4 3.944 4 3.561
21 Aphidicolin glycinate 303,812 4 3.982 – –
22 ARA-C 63,878 3.3 2.758 4 3.509b
23 Asaley 167,780 4.1 5.741a 4.1 3.821b
24 AZQ 182,986 3.8 3.796 4 3.105b
25 Baker’s soluble antifol 139,105 3 3.375 3 3.263
26 BCNU 409,962 3.3 2.438 3.5 3.076b
27 Beta-TGDR 71,261 2.9 2.844 2.9 2.879
28 Bisantrene HCL 337,766 3.9 4.213a 5.2 5.141
29 Brequinar 368,390 3.3 3.975a 3.3 3.544
30 Busulfan 750 3.6 3.639 3.6 2.536
31 Camptothecin 94,600 4.2 4.138 4.4 4.292
32 Camptothecin analog 295,500 4 4.175 – –
33 Camptothecin analog2 606,985 4 3.801 – –
34 Camptothecin analog3 295,501 4 4.089 – –
35 Camptothecin butylglycinate ester hydrochloride 606,499 4.8 4.229 – –
36 Camptothecin ethylglycinate ester hydrochloride 606,497 4 4.165 – –
37 Camptothecin glutamate HCL 610,459 4 4.300 – –
38 Camptothecin hemisuccinate sodium salt 610,456 4 4.154a – –
39 Camptothecin lysinate HCL 610,457 4 4.197a – –
40 Camptothecin phosphate 610,458 5 4.193a – –
41 Camptothecin, 9-methoxy- 176,323 4 4.290a – –
42 Camptothecin, acetate 95,382 4 3.769a – –
43 Camptothecin, hydroxy- 107,124 4.1 4.169 4.1 4.119b
44 Camptothecin, NA salt 100,880 3.6 3.824 4.3 4.378
45 Camptothecin,20-O-((4-(2-hydroxyethyl)-1-piperazino)OAC 374,028 4 4.326a – –
46 Camptothecin-20-O-(N,N-dimethyl)glycinate HCL 618,939 5 4.428 – –
47 CCNU 79,037 3.5 3.401 3.7 3.446
48 Chlorambucil 3,088 3.1 3.461 3.2 3.309
49 Chlorozotocin 178,248 2.9 3.454 2.9 3.290b
50 Clomesone 338,947 2.3 2.998a 2.3 2.312
51 Colchicine 757 3.2 3.792 3.3 3.679
52 Colchicine derivative 33,410 4 3.899a – –
53 Cyanomorpholinodoxorubicin 357,704 4.6 4.554 4.6 3.577
54 Cyclocytidine 145,668 3 3.134a 3 2.953b
55 Cyclodisone 348,948 2.9 3.253 2.6 2.532
56 Daunorubicin 82,151 3.9 4.237 4.1 3.760b
57 Deoxydoxorubicin 267,469 3.9 4.230 3.8 3.829
58 Dianhydrogalactitol 132,313 3.8 3.071 3.8 3.175
59 Dichlorallyl lawsone 126,771 3.6 3.560 3.6 3.376
60 Dolastatin 10 376,128 8 8.000 – –
61 Doxorubicin 123,127 4.7 4.238 – –
(continued on next page)
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accuracy to different systems in less time and less cost from
the computational point of view. In concurrence with the
Density Functional Theory results, energy state of the stan-
dard condition of a polyelectronic framework can be explained
through the combined electronic density, and truth be told, the
utilization of electronic density rather than wave capacity for
determining the energy establishes the base of DFT (Larif et al.,
2013), utilizing the B3LYP utilitarian (Becke, 1993; Lee et al., 1988)
and a 6-311G* basis set.
The B3LYP hybrid functional of DFT method uses Becke’s
three-parameter functional (B3) and integrates a mixture of HF
with DFT exchange terms related with the gradient corrected
















62 Fluorodopan 73,754 2.6 3.207a 2.6 3.082b
63 Ftorafur (pro-drug) 148,958 3 3.008 3 3.157
64 Glycinate 364,830 4 4.220 – –
65 Guanazole 1,895 2 2.225a 2 2.272
66 Hepsulfam 329,680 2.6 3.104 2.6 3.161b
67 Hycanthone 142,982 4.2 4.097 3.6 3.184
68 Hydroxyurea 32,065 2.6 2.481 2.7 2.813
69 Inosine glycodialdehyde 118,994 2.6 3.481 2.6 3.402
70 L-Alanosine 153,353 3.3 3.096a 3.3 3.127
71 Macbecin II 330,500 4 3.606a – –
72 M-AMSA 249,992 3.9 4.125 4.6 4.579
73 Maytansine 153,858 4 3.983 4.1 4.599
74 Melphalan 8,806 3.6 3.143 3.7 3.528
75 Menogaril 269,148 4.2 4.450 1.1 2.007
76 Methotrexate 740 3.6 3.192 3.6 3.655
77 Methotrexate derivative 174,121 7 4.421* – –
78 Methyl CCNU 95,441 3.7 3.370 3.6 5.014b
79 Mitomycin C 26,980 4 2.921 4.7 3.257*
80 Mitoxantrone 301,739 4.7 4.048 5.6 5.780
81 Mitozolamide 353,451 2.9 2.841 2.9 2.985
82 Morpholinodoxorubicin 354,646 4.9 4.616 4.7 4.290b
83 N-(phosphonoacetyl)-L-aspartate (pala) 224,131 2 1.625 2 2.615b
84 N,N-Dibenzyl daunomycin 268,242 4.3 4.597 4.3 4.137
85 Nitrogen mustard 762 3.5 3.200 4.2 3.189
86 Oxanthrazole 349,174 3.6 3.868 3.6 4.511b
87 PCNU 95,466 2.9 3.322 2.9 3.057
88 Piperazine drugsmainator 344,007 3 3.056 3 3.107
89 Piperazinedione 135,758 3 3.601 3.1 3.360
90 Pipobroman 25,154 3.3 2.935 3.3 2.897
91 Porfiromycin 56,410 3 3.050 3 3.302
92 Pyrazofurin 143,095 2.3 2.795 2.3 3.260
93 Pyrazoloacridine 366,140 4.7 3.893 4.3 4.361
94 Pyrazoloimidazole 51,143 2 2.478 2 2.553
95 Rhizoxin 332,598 4 3.847 4.3 4.583
96 Rubidazone 164,011 4.3 4.491 4.2 3.937
97 Spirohydantoin mustard 172,112 3.6 3.721 3.6 3.427b
98 Taxol 125,973 4 4.523 4.6 3.909
99 Teroxirone 296,934 2.6 3.078a 2.7 3.453
100 Thiopurine1 363,812 3.1 3.550a 3.2 3.082b
101 Thiocolchicine 361,792 4 3.779 – –
102 Thioguanine 752 3.6 3.416 3.9 3.357
103 Thio-tepa 6,396 3 3.355 3.1 3.301b
104 Triethylenemelamine 9,706 1 1.331 4.1 3.303
105 Trimetrexate 352,122 3.7 3.605 3.6 3.574
106 Trityl cysteine 83,265 3.9 3.554 3.9 3.859
107 Uracil nitrogen mustard 34,462 3.4 3.167 3.4 3.106
108 Vinblastine sulfate 49,842 5.6 4.351 6 5.678
109 Vincristine sulfate 67,574 3.1 4.357 3.6 4.395
110 VM-26 122,819 4.6 4.167 4.7 4.112
111 VP-16 141,540 3.1 3.989 3.4 4.155
112 Yoshi-864 102,627 2 3.304 2 2.694
a and b represent test sets for MOLT-4 and P388 leukemia cell lines respectively.
* identifies compounds found outside the applicability domain of the model.
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correlation functional of Lee, Yang and Parr (LYP). The orien-
tation of all chemicals under investigation was controlled by
upgrading every single geometrical variable with no equilib-
rium restraints. The Spartan files of the optimized compounds
were then saved in SD file format, which is the recommended
input format in PaDEL-Descriptor software V2.20 (Yap, 2011),
despite the fact that different formats, for example, SMILES or
MOL, are upheld. It is basic to take note that a portion of the
compounds in our dataset, for example, the camptothecin de-
rivatives, were unable to be identified in chemicalbook, in light
of the fact that they had no CAS registry number.
Afterwards, we calculated 1875 descriptors (1444 1D, 2D de-
scriptors and 431 3D descriptors), molecular descriptors, using
the paDEL program (PaDEL-Descriptor, 2014) for example, atom-
type electrotopological state descriptors, McGowan volume,
molecular linear free energy relation descriptors, ring counts,
2D-Autocorrelations, Aromaticity Indices, Randic Molecular Pro-
files, Radial Distribution Functions, Functional Groups, Atom-
Centred Fragments, Empirical and Properties, WHIM, Petitjean
shape index, count of chemical substructures identified by
Laggner, while binary fingerprints and count of chemical sub-
structures identified by Klekota, Roth and Frederick (Klekota
and Roth, 2008), Dragon descriptor software (Talete, 2007; Mauri
et al., 2006) were also used to calculate some other descrip-
tors such as 3D-MoRSE descriptors, GETAWAY descriptors,WHIM
descriptors and Drug-like indices. We likewise incorporate into
the analyses 5 other molecular descriptors calculated from the
DFT computation (dipole moment, energy of the HOMO and
LUMO molecular orbitals, total energy and HOMO–LUMO gap).
2.3. Data normalization
The ascertained molecular descriptors were standardized by
means of a technique preserve range (maximum and minimum)
and the scattering of the descriptors (standard deviation/
variance) was presented before they are changed over into a
N(0,1) dispersion, making the correlation between descrip-
tors (probabilities computation) much less demanding (Brignole
et al., 2013; Nantasenamat et al., 2009).
2.4. Variable selection
Selecting the most pertinent descriptors for QSAR examina-
tion is one of the vital strides, subsequent to the model
developed taking into account the chose variables. By and large,
here the issue is to discover a gathering of variables from ac-
cessible descriptors so that the inferred model can anticipate
the inhibitory action with least mistake in correlation with the
experimental biological information. Genetic algorithm system
as a selection apparatus was composed in Material studio 7
program (Acclerys Material Studio, 2014) and utilized here. The
Genetic algorithm method (GA) begins by a means of forming
a populace of haphazardly created parameter sets.The use like-
lihood of a given parameter from the active set is 0.5 in any
of the introductory populace sets. The sets are then differen-
tiated agreeing from their objective limits. The parameter set
employed for the GA incorporates mutation 0.1, hybrid 0.9,
populace 10,000, the total model generated was 1000, R2 floor
limit 50%, and target capacity R2/N_par. The type of the target
capacity influences sets that have R2 as high as could be ex-
pected under the circumstances while reducing the quantity
of parameters utilized as descriptors. The higher the score, the
greater the likelihood that a given set will be used for the for-
mation of the best in class of sets. In generating a successful
set to be used a significant number of crossovers between set
substance are encouraged, and additionally changed. The cal-
culation keeps running until the wanted number of generations
is come to and equations relating the experimental biologi-
cal toxicity (pLC50) of the compounds and some descriptors are
used. The best models were taken in light of statistical pa-
rameters such as squared regression coefficient (R2) and leave-
one-out cross-validated regression coefficient (Qcv2).
2.5. Data division
Keeping in mind the end goal to get approved QSAR models,
the dataset was divided into a training and validation or test
set. This division was performed such that values from both
the training set (80% of the compounds) and test sets (20 re-
maining percent) are circulated inside of the entire descriptor
space involved by the whole dataset, and for every point in the
test set a corresponding value or one close in magnitude is
chosen in the training set.This division guarantees that a com-
parative guideline can be utilized for predicting the toxicity of
the test set. Kennard–Stone Algorithm will be applied for di-
viding dataset into a training and test set (Kennard and Stone,
1969).
2.6. Model development
MLR is a strategy utilized for displaying direct relationship
between the toxicity (pLC50) and molecular descriptors evalu-
ated in numerical units. The model is fit such that the
standardized residuals between the experimental and pre-
dicted values of the dataset are minimized. The model makes
a relationship as a straight line that best approximates all the
individual data points. In regression examination, the mean
of the toxicity Y variable (pLC50) was found to be dependent
on the molecular descriptors x. MLR examination extends this
idea to consolidate more than one independent variable. Re-
gression model takes the structure:
Y b x b x b x= + +1 1 2 2 3 3
where Y is the response variable (pLC50), ‘b’s are regression co-
efficients for a corresponding ‘x’s which are the independent
variables representing molecular descriptors in this case, finally
‘c’ is the regression constant or intercept.
2.7. Evaluation of the QSAR models
The Developed QSAR models are evaluated using the follow-
ing statistical parameters: n (number of compounds in
regression); K (number of variables (descriptors)); DF (degree
of freedom); optimum component (number of optimums); R2
(the squared correlation coefficient); F test (Fischer’s value) for
statistical significance; q2 (cross-validated correlation coeffi-
cient); pred R2 (R2 for external test set); Zscore (Z score evaluated
through the randomization test); rand R2 (highest R2 value in
the randomization test); randq2 (the highest q2 value in the
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randomization test); and finally α (a statistical significance pa-
rameter obtained via the randomization test).
The coefficient of determination R2 is a relative measure of
fit by the regression comparison. It speaks to the piece of the
variety in the experimental activities of the data set clarified
by the regression equation.Then again, a QSAR model is thought
to be prescient, if the accompanying criteria are fulfilled: R2 > 0.6,
q2 > 0.6 and pred R2 > 0.5. The F-test mirrors the proportion of
fluctuation clarified by the model and change because of the
error in the regression. High estimations of the F-test show that
model is statistically significant, while the low standard error
of pred R2se, q2se and R2se demonstrates total nature of the quality
of the model.
2.8. Validation of the QSAR model
The prescient capacity of the QSAR mathematical statement
was determined utilizing the leave-one-out cross-validation
method. The cross-validation regression coefficient (qcv2) was























where ypred, yexp, and y˜ are the calculated, experimental, and
mean estimations of the empirical toxicities respectively. Ad-
ditionally, the exactness of the predictive ability of the QSAR
mathematical statement was evaluated by solving for their F
value, R2 and R2adj. A large F value demonstrates that the pos-
sibility of a chance correlation in the model is a bare minimum.
It has been indicated that a high estimation of statistical at-
tributes is a bit much for the verification of an exceedingly
prescient model (Golbraikh and Tropsha, 2002). Thus, to assess
the predictive capacity of our QSAR model, we utilized the
method depicted by Roy and Roy (2008). The estimations of the
correlation coefficient and coefficient of determination through
the origin (predicted vs. actual activities and vice versa) were
considered using the regression analysis Tool-pack option in
2013 MSExcel program. Other parameters were also deter-
mined and reported as described by the above authors. The
determination coefficient in forecast, Rtest2, was calculated uti-
















where Ypredtest and YTest are the calculated toxicity values for the
test set and the original empirical values respectively. Y¯Training
is the mean of the toxicities or response value of the training
set (Tropsha et al., 2003). Additional assessment of the pre-
dictive ability of the QSAR model using excluded test set
compounds was achieved by calculating the value of rm2 using
the equation.
rm r r rtest test testo
2 2 2 21= − −( )
where rtest2 is the coefficient of determination for the evalua-
tion of the test set using the developed model and rtesto
2 is the
squared correlation coefficient when the plot of the experi-
mental toxicity against predicted values of test set is evaluated
at zero intercept (Golbraikh et al., 2003). The values of k and
k′ (Golbraikh and Tropsha, 2002) are the slopes of the regres-
sion line of the predicted toxicity versus actual toxicity and

















yi and yi are the calculated and empirical toxicities
respectively.
Further measurable ramifications of the relationship between
activity and the descriptors were investigated via randomiza-
tion test (Y-randomization) of the models.The Y segment areas
were mixed and new QSAR models were delivered using same
arrangement of variables as present in the unrandomized
model. We employed the use of a parameter Rp2, which impli-
cates the model R2 for the difference between squared mean
correlation coefficient (Rrand2) of randomized models and squared
connection coefficient (R2) of the nonrandomized model. The
Rp2 parameter was computed by the accompanying math-
ematical statement:
R R R Rp rand2 2 2 2= × −
This parameter, Rp2 , guarantees that the models therefore
created are not gotten by luck. We have expected that the es-
timation of Rp2 was ought to be more prominent than 0.5 for
a worthy model.
2.9. Y-randomization test
To guarantee the created QSAR model is vigorous and not in-
ferred because of chance, the y-randomization test was
performed on the training set data as suggested by Tropsha
et al. (2003). In the randomization test, the MLR models are
made by heedlessly scrambling the toxicity values (pLC50) while
keeping the independent variables (descriptors) unchanged.The
subsequent models are relied upon to have fundamentally low
R2 and cross approved q2 values for a few trials, which affirm
that the created models are vigorous. We performed 10-y-
randomization tests and noticed that for each one of the models
except for one, the estimations of R2 and q2LOO were <0.5. This
test affirms that the created model is powerful and not in-
ferred just because of chance.
2.10. Degree of contribution of selected descriptors
Keeping in mind the end goal to decide the relative signifi-
cance of every descriptor in the linear regression model, we
ascertain institutionalized regression coefficients ( bjs ) through







= = 1, ,…
where bj is the coefficient of determination for descriptor j,
while sj and sY represent the standard deviations of the cor-
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responding values of the descriptor and for the activity,
respectively. bjs statistical significance allows one to assign a
greater importance to those molecular descriptors that exhibit
larger absolute standardized coefficients.
2.11. Evaluation of the applicability domain of the model
Assessment of the applicability domain of the model is viewed
as an indispensable step in accepting that the model is solid
to make forecasts inside of the applicability space for
which it was produced (Tropsha et al., 2003). There are a few
strategies for characterizing the appropriateness space of a
QSAR model, yet we utilized the most ordinarily utilized le-
verage approach as a part of this study (Gramatica et al., 2007).
Leverage of a given chemical compound hi is defined as:
h x X X x i mi i T iT= ( ) =( )−1 1, ,… , where xi is the descriptor row-
vector of the query compound I, and X is the n k× descriptor
matrix of the training set compounds used to develop the
model. As a prediction tool, the warning leverage (h*) is the
limit of normal values for X outliers and it is defined as:
h p n* = +( )3 1 , where n is the number of training compounds,
and k is the number of descriptors in the model. The test com-
pounds with leverages h hi < *are considered to be reliably
predicted by the model. The Williams plot, a plot of standard-
ized residuals versus leverage values, is utilized to translate
the relevance area of the model in terms of chemical space.
The domain of unfailing prediction for external test set mol-
ecules’ is defined as compounds which have leverage values
within the threshold h hi <( )* and standardized residuals no
greater than 2.5α (2.5 standard deviation units), hence they are
accepted as Y outlier. Test set compounds where h hi >( )* are
thought to be unreliably anticipated by the model because of
considerable extrapolation. For the training set, the Williams
plot is utilized to recognize compounds with the best struc-
tural influence h hi >( )* in developing the model.
3. Result and discussion
Two models were designed to help predict the toxicity of anti-
cancer drugs in the body using 112 compounds for MOLT-4 cell
line and 85 compounds for P388 accordingly. With the exten-
sive variety of contrast between the empirical values and the
vast assorted qualities in the structures, the consolidated
dataset of 112 compounds is perfect for preparing and vali-
dating the created model, as the dataset does not experience
the ill effects of predisposition because of the comparability
of the structures. In a QSAR study, for the most part, the nature
of a model is conveyed by its apt and forecast capacity.
The various molecular descriptors as described in PaDEL-
Descriptors version 2.18 and Dragon version 5.5 were calculated
as proposed in the methodology, and these descriptors were
reduced by assessing the possibility of missing values, a zero
test carried out, i.e. a relationship assessment with a cutoff es-
timation of 0.0001, and a multicollinearity test with a cutoff
estimation of 0.80, we have disposed of the doubtlessly pa-
rameters, bringing about 269 parameters. Further extra
parameters were disposed by applying the GFA, and finally in
both cases of P388 and MOLT-4 cell lines 5 descriptors were
chosen for the improvement of the QSAR mathematical
statement.
3.1. QSAR on the toxicity (lc50) of p388 and MOLT-4 cell
line dataset
Genetic algorithm technique inserted in the Accelrys Mate-
rial Studio package version 7.0 (BIOVIA, 2014) was utilized to
choose the ideal number of descriptors, the impacts of the
quantity of the descriptors were researched for one to five de-
scriptors and with the chose descriptors, we have assembled
the direct model utilizing the preparation set information, and
acquired the accompanying mathematical statements.
3.1.1. MOLT cell line
pLC50 3 801 3 563 7
2 809 7 1
= −( ) − ( )
+ ( ) −
. .
.








+ ( ) +
N N outliers d
F test LOF Fr
testtrain = = > =
− =
90 22 2 5 3 00
38 528
, , . ; . ,
. , iedman = 1 28.
N is the number of compounds used as either a training or a
test set, F is the Fisher F statistic and LOF is the Friedman lack
of fit test (Roy et al., 2015), the number of outliers given as d
was determined using Williams plot, a Euclidean distance based
applicability domain was reported by Tropsha and Grammatica
(Grammatica et al., 2010; Tropsha and Golbraikh, 2007).
3.1.2. P388 cell line
pLC50 1 139 3 1 755
3 051 75 4 857 14
= − ( ) + ( )
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+ ( ) +. .
N N outliers
F test LOF Frie
train test= = > =
− =
68 17 2 5 1 00
30 426
, , . . ,
. , dman = 0 55.
F test which measures the variance that compares two models
to check whether the less simple model is more dependable
than the less perplexing one, its value for the selected models
were more significant than the pool of models generated
through GA-MLR, though our research suggests that the MOLT-4
model is more significant when compared on the bases of F-test
only.
3.2. QSAR model validation
Since it was reported that R2 and R2adj can be effortlessly altered
by expanding the quantity of terms in a QSAR model, we needed
to consider the cross-relationship coefficient (Q2CV) as the re-
stricting element for a number of descriptors to be utilized as
a part of the accepted model. It was seen that the (Q2CV) value
expanded until the quantity of descriptors in the compari-
son came to 5. In this way, the quantity of descriptors was
limited to 5 in both accepted QSAR models for P388 and MOLT-4.
The statistical results of the models were presented in
Table 2. The QSAR model developed in this study was
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statistically (R2 = 0.696, R2adj =0.678, Q2CV = 0.644) and (R2 = 0.711,
R2adj = 0.687, Q2CV = 0.641) best fitted for MOLT-4 and P388 cell
lines respectively and therefore was utilized in predicting the
toxicity component (pLC50) of the test sets. The result of the
calculated toxicity of the compounds using the model is pre-
sented alongside its experimental values in Table 1.
The predicted R2 values for the test set of MOLT-4 and P388
cell lines are also reported in Table 2 and their values are given
as 0.679 and 0.662 respectively. This parameter confirms with
the criteria for a QSAR model to be exceptionally prescient.The
calculated values (pLC50) for the compounds in the prepara-
tion and test sets utilizing the pLC50 mathematical equations
for P388 and MOLT were plotted against their experimental pLC50
values in Figs. 1 and 2 separately. These plots can be seen to
relay the information from Table 1, i.e. the evaluated values
for the pLC50 are in good agreement with the their empiri-
cally determined values. Likewise, the plots of the standardized
residual for the anticipated estimations of pLC50 for both the
preparation and test sets against the experimental pLC50 values
are shown in Figs. 3 and 4 for P388 and MOLT-4 cell lines re-
spectively. As can be seen the model did not demonstrate any
















































ˆ ≥ 0.6 0.687 0.678
R Qcv2 2= The average coefficient of determination for the curve of
predicted activity versus experimental activity for test sets
used for cross validation
>0.5 0.641 0.644
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− r2 is the coefficient of determination for the curve of predicted
activity versus experimental activity for external validation








′ ro′2 is the coefficient of determination for the curve of
experimental activity versus against predicted activity for
external validation (test set) passing through the origin
<0.1 0.050 0.002
k Slope of predicted activity versus experimental activity for
external validation (test set) passing through the origin
0.85 < =k < = 1.15 0.955 1.006
k′ Slope of experimental activity versus against predicted activity
for external validation (test set) passing through the origin



























ˆ >0.6 0.662 0.679
n is the number of molecule in the training set, m is the number of descriptors in the model, z is the number of molecule in the test or evalu-
ation set.
ytr is the experimental activity value for the training set, yˆtr is the predicted activity value for the training set and ytr is the average or mean
of the experimental activity value for the training set.
yext is the experimental activity value for the test or evaluation set, yˆext is the predicted activity value for the test or evaluation set.

























Fig. 1 – The predicted toxicity values (pLC50) against the
experimental values for the training and test sets of the
compounds on P388 leukemia cell line.
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relative and systematic error, on the grounds that the prolif-
eration of the residuals on both sides of zero is irregular.
The chemical and biological data portrayed by the prepa-
ration set, and caught by a significant arrangement of
descriptors, might be thought to be the space of pertinence of
the QSAR model, in spite of the fact that this is absolutely reliant
on the training set, whose toxicities were modeled, but many
a times different molecules considered may deviate structur-
ally from the training set hence setting back the availability
of the model for that study. Because of this limitation the data
set were selected with different structural motifs as reported
earlier in this work, so that it will be possible to capture most
of the chemicals within the domain of a model. The leverage
qualities were computed for each compound in the dataset and
plotted against standardized residuals, and it consents to a
graphical finding of both the anomalies and the compelling
chemicals in a model. Figs. 5 and 6 demonstrate the Williams
plot for P388 and MOLT-4 dataset, applicability space is set up
inside a squared region within ±2.5 mapped for residuals and
a leverage threshold h* ( h p n
o
* = 3 , where po is the quantity of
model parameters and n is the number of compounds) (OECD,
2007; Roy et al., 2015). From our result it is evident that all the
compounds of the training set and test set for P388 dataset were





















Fig. 2 – The predicted toxicity values (pLC50) against the
experimental values for the training and test sets of the
compounds on MOLT-4 leukemia cell line.






















Fig. 3 – The standardized residuals against the
experimental toxicity (pLC50) values for the training and
test sets on P388 leukemia cell line.
























Fig. 4 – The standardized residuals against the
experimental toxicity (pLC50) values for the training and
test sets on MOLT-4 leukemia cell line.
























Fig. 5 – The Williams plot, the plot of the standardized
residuals versus the toxicity (pLC50) leverage value for P388
dataset.
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within the square area, all with an exception of about 11 com-
pounds which were not within the chemical space domain or
the model i.e. the leverage values are lower than the caution-
ary h* value of 0.210, though this was attributed to strong
differences in their chemical structures compared to the out-
standing compounds in the data set, Mitomycin having the ID
number (79) was found to be an outlier. This could be attrib-
uted to wrong or false experimental result used in developing
the model since it was found within the chemical space or ap-
plicability domain of the model. Furthermore, the chemicals
found outside the applicability domain of the model were <15%
of the total dataset indicating the wide spread of the model
in predicting random molecules with different structures.
The Williams plot for MOLT-4 shown in Fig. 6 reveals that
only 3 outliers were identified and two of the compounds
(ID = 11 and 12) i.e. 9-amino-2(R,S)-Campothein and Acivicin
were outside the chemical applicability space of the model
which demonstrates the powerlessness of the model to an-
ticipate the toxicity of these compounds can be linked to the
descriptors which gives little or no information on these com-
pounds. Eight (8) other compounds were also found outside
the applicability domain, although Uzairu’s plot (Figs. 7 and 8),
which is the plot of normalized mean distance of the molecu-
lar descriptors against the standardized residuals of their
toxicities, suggests the fact that the other (8) compounds were
results of structural differences with other compounds in the
dataset; however the model used is significantly effective in
predicting compounds of different structural motifs and analogs.
The Williams plot for the dataset shown in Fig. 6 sets up
applicability space of the model inside ±2.5d and a leverage
threshold h* = 0.164 for MOLT-4 data set. Every one of these com-
pounds has its leverage value more prominent than the
calculated h* value and could be high leverage compound
swaying the execution of the model, while the outstanding com-
pounds were within the margin for the applicability space of
the model. Be that as it may, all their residuals are low and
within an acceptable limit. Therefore, these compounds are re-
garded important in fitting the model performance however
irrelevant or erroneous to be erased from the preparation set,
and likewise the model can be used with high certainty that
all compounds have similar analogs as those in the applica-
bility space or domain of the model.
Keeping in mind the end goal to survey the power of the
model, the Y-randomization test was utilized in this study
(Tropsha et al., 2003). Y-randomization test asserts whether the
model is gained by chance correlation, and is a bona fide
structure–activity relationship to approve the adequacy of the
preparation set. Y-randomization test was used to contrast the
stemmed scores and the score of the first QSAR model pro-
duced with non-randomized information.
The steps followed during the randomization test include
the repeated scrambling of the toxicity information in the model




























Fig. 6 – The Williams plot, the plot of the standardized
residuals versus the toxicity (pLC50) leverage value for
MOLT-4 dataset.
























Fig. 7 – The Uzairu’s plot of the normalized mean distance
versus the standardized residuals of the toxicity (pLC50) for
P388 dataset.
























Fig. 8 – The Uzairu’s plot of the normalized mean distance
versus the standardized residuals of the toxicity (pLC50) for
MOLT-4 dataset.
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preparation set molecules, after which they were utilized to
create QSAR equations, and after that at long last contrast-
ing this subsequent scores and the score of the first QSAR
mathematical statement produced with non-randomized in-
formation. In the event that the pLC50 values calculated with
the randomized model are practically identical to that of the
first mathematical statement, then the arrangement of per-
ceptions is not adequate to bolster the model. The new QSAR
models (after a few reiterations) would be relied upon to have
low R2 and Q2LOO values (Table 3a and 3b). In the event that the
inverse happens, then a satisfactory QSAR model cannot be
acquired for the particular modeling system. The results of
Table 3a and 3b for MOLT-4 and P388 respectively indicate that
an acceptable model is obtained by GA–MLR method, and the
model created is factually noteworthy and vigorous.
The inter-correlation of the descriptors utilized as a part of
the QSTR model was low (underneath 0.8), which is in agree-
ment to the study, that for a statistically significant model, it
is vital that the molecular descriptors included in the math-
ematical equation ought not be highly correlated with one
another (Deswal and Roy, 2006). To further check the
intercorrelation of descriptors, VIF investigation was per-
formed. In MOLT-4 equation, the VIF estimations of these
descriptors in Table 4a are given as 1.087 (n-Isopropyl), 1.424
(GATS7p), 2.116 (SpMax7_Bhm), 1.007 (minHBint8), 1.572
(nF10ring) and for P388 model 1.016 (GATS3e), 1.024 (SaaaC),
2.398 (RDF75u), 7.565 (RDF145u), 5.484 (RDF145s) respectively,
which are not greater than the optimum value of 10 (Jaiswal
et al., 2003; Shapiro and Guggenheim, 1998). Fulfilled by the
robustness of the QSTR model created utilizing the training set,
we treated the remaining test set with the model. As the ex-
perimental values for the pLC50 of these inhibitors are as of
now accessible, this provided us with the ample opportunity
of testing the prediction power of the QSTR model for fore-
casting the toxicity of new compounds.
3.3. Interpretation of descriptors in p388 and MOLT-4
models
To look at the relative significance, and the impact of every mo-
lecular descriptor in the models, the mean effect (MF) for each
descriptor was ascertained and reported in Table 4a and Table 4b
respectively for MOLT-4 and P388 cell lines. This was achieved

















Table 3 – (a) R2Train and Q2LOO values after several
Y-randomization tests for MOLT-4 cell line. (b) R2Train and
Q2LOO values after several Y-randomization tests for P388
cell line.
Iteration R R2 Q2
a
Random 1 0.101103 0.010222 −0.08921
Random 2 0.204824 0.041953 −0.04907
Random 3 0.187509 0.03516 −0.06742
Random 4 0.273986 0.075068 −0.02015
Random 5 0.228156 0.052055 −0.02738
Random 6 0.112286 0.012608 −0.18838
Random 7 0.083815 0.007025 −0.13816
Random 8 0.125325 0.015706 −0.10573
Random 9 0.174502 0.030451 −0.13182







Random 1 0.140259 0.019673 −0.10917
Random 2 0.287113 0.082434 −0.04776
Random 3 0.147206 0.02167 −0.15027
Random 4 0.103906 0.010796 −0.0763
Random 5 0.35012 0.122584 −0.10509
Random 6 0.216846 0.047022 −0.12951
Random 7 0.111975 0.012538 −0.14734
Random 8 0.166797 0.027821 −0.11674
Random 9 0.258862 0.067009 −0.32268






Table 4 – (a) Specification of entered descriptors in genetic algorithm multiple regression model of MOLT-4. (b)
Specification of entered descriptors in genetic algorithm multiple regression model of P388.
Descriptors Definition bjs VIF MF
A
Isopropyl (fragment counts) Number of isopropyl fragment present 0.011617 1.086679 0.034373
GATS7p Geary autocorrelation – lag 7/weighted by polarizabilities −0.20895 1.423644 −0.61826
SpMax7_Bhm Largest absolute eigenvalue of Burden modified matrix – n 7/weighted by
relative mass
0.573491 2.116336 1.696864
minHBint8 Minimum E-state descriptors of strength for potential hydrogen bonds of
path length 8
−0.09459 1.007349 −0.27987
nF10Ring Number of 10-membered fused rings 0.056406 1.572089 0.166896
b
GATS3e Geary autocorrelation – lag 3/weighted by Sanderson electronegativities −0.12212 1.016635 −3.51952
SaaaC Sum of atom-type E-State: ::C: 0.040321 1.023991 1.162028
RDF75u Radial distribution function – 075/unweighted 0.130909 2.397785 3.772673
RDF145u Radial distribution function – 145/unweighted −0.1492 7.564799 −4.29984
RDF145s Radial distribution function – 145/weighted by relative I-state 0.134795 5.483749 3.88466
330 b en i - s u e f un i v e r s i t y j o u rna l o f b a s i c and a p p l i e d s c i e n c e s 5 ( 2 0 1 6 ) 3 2 0 – 3 3 3
MFj is given as the mean effect for the considered molecu-
lar descriptor j, while β j is the coefficient of the descriptor j,
dij represents the values for the target descriptors of each mol-
ecule, and m is the total number of descriptors in the model.
The descriptors used in MOLT-4 model are presented below
with their individual corresponding effects to the model
n-isopropyl defined as the number of isopropyl fragment present
in a compound i.e. , which in recent time has been
associated with isopropanol poisoning (Martinez et al., 1986),
hence the hydrogen atom present could be hydrolyzed, thereby
promoting the toxic nature of a drug. The mean effect is poorly
felt in the model since its value (0.0344) is low.
GATS7p is a 2D autocorrelated descriptor which is defined
as Geary autocorrelation – lag 7/weighted by polarizabilities,
it was developed by Todeschini and Consonni (2009). The mean
effect of the descriptor was found to be (−0.618) and pre-
sented in Table 4a, it negatively influences the model, its value
was seen to significantly reduce the value of pLC50 in MOLT-4
model, hence increase in overall polarity of the drugs in-
creases the toxicity of the compound. This was found to be in
agreement with the polar descriptor determined.
SpMax7_Bhm a Burden Modified Eigenvalues Descriptor is
defined as the Largest absolute eigenvalue of Burden modi-
fied matrix – n 7/weighted by relative mass, it can be related
to the molecular weight of the drug, the mean effect of the de-
scriptor was calculated as 1.697, its positive sign indicates that
an increase in the overall molecular weight of the compound
increases the pLC50 values of the compounds, hence decreas-
ing the toxicity of the compounds and less bulky side groups
are needed in order to decrease the toxicity of a cancer drug.
More research on the target site of the drugs could confirm its
stability at a contact point.
minHBint8 is an Electrotopological StateAtom Type 2D De-
scriptor. It was defined by Hall and Kier (1995) to be the
Minimum E-State descriptors of strength for potential hydro-
gen bonds of path length 8. The mean effect of the descriptor
was −0.280, which indicates that by altering the value of the
molecular descriptor positively in the model, an increase in
the toxicity of that drug would be observed.
The last of the five descriptors used in predicting the tox-
icity of drugs on MOLT-4 cell line is nF10Ring, which is a Ring
Count Descriptor defined by Todeschini and Consonni (2009)
as the number of 10-membered fused rings in a given drug.
The mean effect of the descriptor (0.167) suggests the signifi-
cance of this descriptor to the equation and hence increasing
its value positively influences the value of the pLC50 for MOLT-4
cell line.
GATS3e a 2D Autocorrelation Descriptor was defined as Geary
autocorrelation – lag 3/weighted by Sanderson electronega-
tivities, the mean effect (−3.519) of the descriptor was found
to negatively influence the values of pLC50 in the model and
hence increasing the toxicity of the compounds, while SaaaC
which is an Electrotopological StateAtom Type Descriptor was
defined as Sum of atom-type E-State (C), the number of carbon
atoms present in a compound.The mean effect is given as 1.162
which affected the model the least. Additional molecular de-
scriptors used in the pLC50 model for P388 cell line were found
to contribute over 70% effect on model; these are RDF 3D type
Descriptors.
RDF75u, RDF145u and RDF145s are RDF 3D type Descrip-
tor, RDF75u is defined as Radial distribution function – 075/
unweighted, while RDF145u and RDF145s are defined as Radial
distribution function – 145/unweighted and Radial distribu-
tion function – 145/weighted by relative I-state respectively.Their
corresponding mean effects are reported in this work as 3.773,
−4.299 and 3.885. The result indicates that RDF145u contrib-
utes the most in all the descriptors, its value also supports the
degree of contribution of the descriptors calculated and pre-
sented in Table 4b, but the sign of the descriptor is negative,
hence an increase in the value of RDF145u in the model will
decrease the value of pLC50 for the compounds in P388 cell line
thereby leading to an overall increase in the toxicity of the com-
pounds under investigation.
3.4. Lipinski failures and lipophilicity study
The data set were subjected to further study to better under-
stand the relationship of their pLC50 values with other toxicity
indices. These molecular descriptors of the compounds were
used as data set for both MOLT-4 and P388 toxicity study, such
as aPol, ALogP, ALogp2, MLopP and XLogP. Others including po-
larity index, lipoaffinity index and Lipinski failures were
calculated using paDEL and the Dragon programs. The Pearson
correlation matrix of these descriptors with their toxicity values
is determined and it was evident that MLogP, polar and aPol
were mildly correlated to toxicity of MOLT-4, the lipoaffinity
index which defines the affinity of the drugs to hydrophobic
environment is about (40–45)% in both cell line cases, indicat-
ing that even though some part of these drugs are hydrophobic
in nature, it is not enough to significantly affect the toxicity
of the drugs under study. While Lipinski failures were also used
to assess the drug likeness of the compounds, it indicates that
some of the drugs about 40% may not be orally active in
humans, hence those drugs can only be committed locally and
best intravenously. Other parameters such as the polarity and
apol represent some atom polarity in the drugs, including im-
plicit hydrogens for apol. They were found to mildly increase
the toxicity of the drugs. Mannhold LogP (MLogP) was found
to be the most significant of all the considered descriptors that
could be responsible for the toxicity of most cancer drugs. Its
value was reported with other results in Table 5 to 67.3% and
59% correlation to the toxicity of the drugs.
4. Conclusion
The expanding enthusiasm for the utilization of QSARs for pre-
dicting toxicity of drugs in pharmaceutical industries has been
a keen area for most researchers recently, since they could be
implemented under the circumstances for giving an early tox-
icity screen before being extensively used commercially. This
reason encouraged the development of two models (pLC50 for
MOLT-4 and P388) which could be utilized for screening tox-
icity in new anticancer compounds before subjecting them for
further analysis. The models developed were found to prop-
erly predict the toxicities of the compounds in the dataset. The
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models were validated internally and externally using statis-
tical approaches such as Q2CV and R2pred respectively. Further
analysis was carried out to validate the models by using cri-
teria such randomization test, R2p, r2m, k and k′ to ascertain the
predictive power of the models.
Appendix: Supplementary material
Supplementary data to this article can be found online at
doi:10.1016/j.bjbas.2016.11.003.
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